


POPular CABG

#ESCCongress



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Patients scheduled for CABG with ≥ 1 saphenous vein graft (SVG) were randomized in a 1:1 fashion to either ticagrelor 90 mg BID or placebo. Patients were followed for 1 year.



RESULTS

- Primary endpoint, SVG occlusion at 1 year on CT/coronary angiography, ticagrelor vs. placebo: 10.5% vs. 9.1%; OR 1.29, 95% CI 0.73-2.30 (p = 0.38)
- 30-day BARC 3-5 bleeding: 2.4% vs. 1.6% (p = 0.51); 1-year BARC 3-5 bleeding: 3.6% vs. 2.4% (p = 0.42)
- Revascularization: 5.3% vs. 0.8% (p < 0.05); ACS/MI: 2.4% vs. 1.2%

CONCLUSIONS

- Ticagrelor is not superior to placebo for SVG patency at 1 year following CABG. Bleeding was higher with ticagrelor, but not statistically significant. Almost all patients underwent on-pump surgery
- This trial was not powered for clinical endpoints